Tags : Voluntis

Biocon Collaborates with Voluntis on Digital Therapeutics for Insulins

Shots: The two companies collaborated to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. The collaboration allows Biocon to offer Insulia to T2D patients across several markets globally Biocon aspires to reimagine the patient ecosystem by developing a technology-dependent operating model enabling personalization of care, thus going beyond the product […]Read More

BMS Collaborates with Voluntis to Co-Develop Digital Therapies to Treat

Shots: The collaboration will deploy Voluntis’ Theraxium Oncology, a platform for digital therapies in oncology and will evaluate potential solutions to support the management of patients symptoms & remote monitoring by HCPs The focus of the collaboration is to develop digital therapies, providing patients access to a mobile app to support the treatment and track […]Read More

PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired […]Read More

Voluntis’ Oleena Digital Application Receives FDA’s Marketing Approval to Self-Manage

Shots: The US FDA has completed its regulatory review of Oleena software which is a Class II medical device facilitating oncology-related symptoms management and remote patient monitoring Oleena is embedded with clinical algorithms offerings real-time personalized insights and actionable recommendations to the patients for managing their own symptoms while monitoring remote patients will improve clinical […]Read More